Normal breast tissue as well as most breast tumors are dependent on estrogen for growth. Breast tumors often progress to a hormone-independent state which is associated with poor prognosis. It has been proposed that activation of growth factor signaling pathways in the tumor cells may free them from hormonal control. Certain growth factors can mimic estrogen responses by activating the estrogen receptor via its phosphorylation by mitogen-activated protein (MAP) kinase. In this report, however, we show that ®broblast growth factor (FGF), despite activating MAP kinase, is growthinhibitory for estrogen-dependent MCF-7 breast cancer cells. MCF-7 cells treated with FGFs exhibit slower growth than controls in both the presence and absence of estrogen, with a concomitant increase in the number of cells in G0/G1. Expression of a constitutively activated FGF receptor in these cells further decreases their growth rate, which is no longer in¯uenced by FGF treatment. Activation of the FGF signaling pathway also reduces the induction of an estrogen-responsive CAT reporter plasmid by estrogen, an eect which appears to be independent of serine 118 in the estrogen receptor, a MAP kinase target site. The inhibitory eects of FGF are probably mediated through the sustained induction of the cyclin kinase inhibitor p21/WAF1/CIP1, which is upregulated at the mRNA and protein level by FGF. FGF treatment also results in the phosphorylation of STAT1. This upregulation of p21 and phosphorylation of STAT1 is not detectable in T47D breast cancer cells upon which FGF has no inhibitory eect.
Introduction
The principal mitogen for breast epithelial cells is the steroid hormone estrogen but growth factors also play an important role in controlling mammary gland development, morphogenesis, and breast cancer progression (Dickson and Lippman, 1995; Chalbos et al., 1994) . Estrogen acts by activating the estrogen receptor (ER), a member of the nuclear receptor superfamily that dimerizes upon ligand binding, and regulates transcription from ERE (estrogen response element)-containing promoters in a cell-type speci®c manner (Tsai and O'Malley, 1994) . The mechanism by which estrogen acts as a mitogen is still unclear; the consensus until recently was that its mitogenic eect is partially mediated by the induction of growth factor signaling pathways (Dickson et al., 1986) . Recent data however indicate that estrogen action may directly modulate the activity of cell cycle regulatory genes and cause phosphorylation of Rb (Altucci et al., 1996) .
It has been known for some time that growth factors such as EGF and IGF, which are probably derived from the surrounding stromal cells, can act on epithelial cells and modulate their growth. These growth factors are able to activate the estrogen receptor and promote transcription from an EREcontaining promoter in the absence of estrogen. In the reproductive tract EGF can mimic the physiological eects of estrogen (Ignar-Trowbridge et al., 1992; Curtis et al., 1996) . This ligand-independent activation of ER by IGF or EGF has been shown to be mediated through phosphorylation of a serine residue at position 118 in ER by activated MAP kinase (Kato et al., 1995; Bunone et al., 1996) .
A common feature associated with breast tumor progression is a loss of hormone-dependent growth of the tumor cells. It has been suggested that the tumor cells, which are epithelial in origin, may acquire an autocrine or paracrine growth factor-stimulated pathway and thus free themselves from hormonal control (Dickson and Lippman, 1995; Chalbos et al., 1994) . Signaling through a variety of growth factor receptors including TGFa, EGF, IGF and FGF has been implicated in such autocrine growth (Ethier, 1995) .
The ®broblast growth factors (FGFs) are a family of angiogenic factors that are potent mitogens for ®broblast and endothelial cells (Basilico and Moscatelli, 1992) , and have been implicated in epithelial-stromal interactions in hormone-responsive tumors. It has been well established that FGF signaling plays an important role in MMTV-induced mouse mammary tumors, since both FGFs and their receptors have been found to be activated in MMTV-induced mammary tumors (Murakami et al., 1990; Muller et al., 1990; Shackleford et al., 1993; MacArthur et al., 1995) . On the other hand, while some reports support the hypothesis that human breast tumor progression may be mediated by the autocrine activation of the FGF signaling pathway (McLeskey et al., 1993; Adnane et al., 1991) , more recent data point to a negative regulatory role for these factors Wang et al., 1997) . Furthermore, FGF-1 and FGF-2 levels are lower in breast tumor biopsies than in normal breast, suggesting that in breast tissue these factors may have an inhibitory role that is lost as the tumors progress (Bansal et al., 1995; Yiangou et al., 1997) . Therefore we decided to investigate the cross-talk between FGF signalling and estrogen-response pathway in breast epithelial cells.
In this report we analyse the eect of FGF signaling on the estrogen-responsive breast carcinoma cell lines MCF-7 and T47D. We show here that FGF signaling is growth-inhibitory for MCF-7 cells, and that it can down-regulate the estrogen response in these cells despite activating the MAP kinase pathway. Activation of FGF signaling in MCF-7 cells results in a dramatic and sustained upregulation of the cyclin dependent kinase inhibitor p21/WAF1 and an accumulation of cells in G1. FGF treatment also induces the phosphorylation of STAT1 (Signal Transducers and Activators of Transcription), a protein in the JAK-STAT signaling cascade that promotes the expression of a speci®c set of genes (Darnell et al., 1994; Ihle and Kerr, 1995) . In contrast, the upregulation of p21 mRNA and protein, and the phosphorylation of STAT1 is not seen in the T47D cells where FGF has no inhibitory eect. These results are consistent with the hypothesis that FGF signaling antagonizes the estrogen response of MCF-7 breast cancer cells and inhibits their proliferation by inducing growth-inhibitory molecules.
Results

Expression of FGFs and FGF receptors in breast cancer cells
The FGF family of growth factors consists of nine members described so far. We analysed the repertoire of FGFs expressed in several breast cell lines by RT ± PCR in order to rule out the involvement of autocrine FGF eects in the MCF-7 and T47D cells. A set of primers speci®c for each FGF was designed that was previously used to con®rm the array of FGFs present in prostate stromal and epithelial cells (Ittman and Mansukhani, 1997) . The PCR products were hybridized with DNA probes speci®c for each of the FGFs in order to con®rm the presence or absence of a given PCR product. There was no expression of FGFs 1 ± 7 or 9 in the two estrogen-responsive cell lines examined although other ER-negative lines showed the presence of FGF-1, FGF-2, FGF-5, or FGF-4 (Table 1) . FGF-8 was originally identi®ed from the SC-3 murine breast carcinoma line and found to be androgen-inducible in some human breast cancer cells (Payson et al., 1996) . MCF-7 cells were positive for FGF-8 expression while T47D cells were negative. All the other estrogenindependent cell lines also showed the presence of FGF-8 mRNA. Primary ®broblasts derived from a breast tumor biopsy were also analysed alongside the total tumor RNA for FGF expression. As expected, the stromal ®broblasts appear to be the primary source of FGF-1, FGF-2, FGF-5, FGF-7 and FGF-9 detected in the tumor sample. A summary of the analysis is shown in Table 1 .
The FGF receptors (FGFR) are encoded by four distinct but homologous genes (FGFR-1, FGFR-2, FGFR-3 and FGFR-4). These receptors are membrane-spanning tyrosine kinases of the immunoglobulin (Ig) superfamily with two or three Ig-loops in the extracellular region (Johnson and Williams, 1993) . Splicing alternatives further give rise to receptor isoforms that can be identi®ed by RT ± PCR (Ittman and Mansukhani, 1997) . The ligand-binding ability of these receptors is non-speci®c and overlapping for the dierent FGFs, with each receptor able to bind more than one growth factor (Ornitz et al., 1996) . The only strict speci®city is seen in a splice variant of FGFR-2 called FGFR-2(IIIb), which binds almost exclusively FGF-7/keratinocyte growth factor. It is generally true that the two splice variants of FGFR-2 are expressed in a mutually-exclusive cell type-speci®c manner, with FGFR-2(IIIb) in epithelial cells and FGFR-2(IIIc) in ®broblasts. However, several breast epithelial lines express both splice variants of receptor 2 (Luqmani et al., 1996) . MCF-7 and T47D cells express all four FGF receptors. Both splice variants of receptor 2 are expressed in MCF-7 cells. Somewhat surprisingly, all other cell lines we examined express only the FGFR-2(IIIc) form. MCF-7 and T47D are estrogen-dependent tumor cell lines, while BT549, MDAMB231, and Hs578T are estrogen-independent tumor lines. HBL100 is an estrogen-independent line from mammary epithelial cells. H578TBst is the normal counterpart of Hs578T. The ®broblast sample was derived from a malignant breast biopsy sample (tumour tissue). (7), no band visible after overnight exposure; (+/7), band visible after overnight exposure; (+), band visible in 1 h exposure; (++) band visible on ethidium bromide stained gel; (+++) strong band on ethidium bromide stained gel; (n.d.), not done FGF inhibits the growth of MCF-7 cells MCF-7 cells are dependent on estrogen for growth. Since fetal calf serum contains steroid hormones, the cells were grown in phenol red-free medium containing 5% charcoal-stripped serum to simulate estrogendepleted conditions. Figure 1 shows that cells in this medium grow slowly, and in the presence of 10 ng/ml FGF-4 there is a further reduction of growth. As expected, addition of 10 nM b-estradiol had a potent growth stimulatory eect. However, the addition of 10 nM b-estradiol and FGF-4 together slowed the growth of the cells compared to estrogen alone ( Figure  1a ). This eect was not seen in the estrogenindependent breast cell lines HBL100, H578T, and BT549 where the addition of FGF-4 or FGF-2 at 1 or 10 ng/ml had no eect on the growth rate (data not shown). In T47D cells, another estrogen-dependent cell line which expresses approximately one-fourth as much estrogen receptor as the MCF-7 cells (Horwitz et al., 1978) , FGF-2 (data not shown) and FGF-4 had no inhibitory eect and possibly a slight stimulatory eect ( Figure 1b) .
DNA content analysis showed that in untreated cycling cells in estrogen deprived medium, about 63% of the cells had a G1/G0 DNA content while treatment with 10 ng/ml FGF-2 increased this fraction to 73%. The percentage of cells in S-phase was concomitantly reduced from 27% to about 14%. The accumulation of cells with a G1 DNA content was somewhat lower in FGF-4 treated cells although the eect was still apparent (data not shown). The addition of estradiol was growth stimulatory with an increase in S phase and G2/M cells. Addition of estradiol and FGF-2 to the cells showed that estrogen counteracted the inhibitory eect of FGF-2 (Table 2) .
To ensure that the inhibitory eect we observed was mediated by FGF signaling through the FGF receptor and not by a transmodulatory mechanism, we expressed a constitutively activated FGFR-2 in MCF-7 cells. The activated receptor has a cysteine to arginine mutation at position 382 in the transmembrane domain. We have previously shown that this receptor is capable of transforming NIH3T3 cells and is tyrosine-phosphorylated even in the absence of ligand (Li et al., 1997) . Several clones were isolated and those expressing the highest levels of FGFR-2/ C382R were selected for further study. Clone 1021 #18 which expressed the highest level of the mutant receptor grew visibly slower than the parental cells and had a longer doubling time. The cells were still estrogen-responsive and the addition of FGF-4 had no further repressive eect on growth ( Figure 1c) .
The inhibitory eect of FGF on MCF-7 cells can also be seen at the level of DNA synthesis. Cells were kept in phenol red-free DMEM containing 5% charcoal-stripped serum for 48 h and treated with the indicated doses of FGF-4 and estradiol. Twelve hours later the cells were pulsed with 3 H-thymidine and the radioactivity precipitated by TCA was counted. Figure  2 shows that in the absence of estrogen, FGF-4 treatment at 1 and 10 ng/ml reduces the incorporated counts two and fourfold respectively. This eect is still manifest in the presence of estrogen, but the inhibitory eect is diminished, again indicating that estrogen and FGF have opposing eects on these cells. FGF treatment had no eect on DNA synthesis in 1021 #18 cells, which is consistent with the growth data (data not shown).
FGF can activate the MAP kinase pathway in MCF-7 cells
Activation of erk1 and erk2 are known downstream eects of FGF signaling in ®broblasts. We checked the kinetics of MAP kinase activation in our MCF-7 cells in response to FGF by an in vitro kinase assay. Cells were kept in 0.5% CS-FCS overnight (serum does not contain signi®cant levels of FGF activity). FGF-2 or MCF-7 cells were grown in phenol red-free medium containing 5% charcoal stripped serum for 2 days and then treated as described for 24 h. Cells were harvested and analysed for DNA content FGF-4 at 100 ng/ml was applied for 30 min and cells were harvested. To assess MAP kinase activity, active MAP kinase was immunoprecipitated and used in a kinase assay with elk-1 as substrate. The kinase assay was subjected to Western blotting with an antibody that speci®cally recognizes phosphorylated elk-1. Figure 3a shows that FGF-2 and FGF-4 can activate MAP kinase in these cells. EGF treatment at 100 ng/ml for the same time was a less potent activator of MAP kinase in these cells, while estrogen treated samples had undetectable levels of phosphorylated elk-1. Anti-active MAP kinase antibodies were also used to speci®cally detect tyrosine-phosphorylated erk1 and erk2 in MCF-7 cells treated with FGFs. A time course of MAP kinase activation shows that the active MAP kinase signal is still seen after 5 h of treatment with 10 ng/ml FGF-4 and the presence of estrogen does not appreciably appear to aect if (Figure 3b ). MAP kinase is activated by FGF with similar kinetics in T47D cells (Figure 3c ). The amount of protein in each lane is equal as can be seen in Figure 9 where the same blot is reused.
Eect of FGF on estrogen-induced gene expression
Factors such as EGF which activate the MAP kinase pathway can activate the estrogen receptor in an estrogen-independent fashion (Kato et al., 1995; Bunone et al., 1996) . We studied the eect of FGF treatment on an ERE-CAT reporter (DETCO) construct transfected transiently in MCF-7 cells. The DETCO has an ERE upstream of a minimal promoter from the TK gene and has been previously used by other researchers to study ER-mediated activation of transcription (Bunone et al., 1996; Trowbridge et al., 1997) . As expected, the CAT activity was strongly induced in cells treated with estrogen. Treatment with 10 ng/ml FGF-4 had little eect on basal activity, but reduced estrogen-induced CAT activity about 2.5-fold from the level induced by estrogen alone. This inhibitory eect of FGF was not observed in similar experiments where DETCO was replaced with a CAT reporter plasmid containing a TK promoter alone (data not shown). We also did a cotransfection with a truncated FGF receptor-2 (Bek 2.0 kb), which we have shown previously to have a dominant inhibitory activity on FGF signaling (Li et al., 1994) . Expression of Bek 2.0 kb considerably decreased the FGFinhibition of CAT activity in the MCF-7 cells. Expression of a construct encoding the wild type FGFR-2 reduced overall CAT activity, presumably due to receptor activation resulting from high levels of expression (Li et al., 1997) , but FGF-mediated inhibition of the estrogen response was still detectable. Cotransfection with a plasmid encoding the activated FGFR-2/C382R strikingly reduced the activity even further although estrogen-inducibility was still maintained. In this case however, as expected, FGF treatment had no eect (Figure 4a ).
To rule out the possibility that the eect was due to a peculiarity of the estrogen receptor in MCF-7 cells, we performed the same experiment in NIH3T3 cells cotransfected with an ER expression plasmid (NIH3T3 cells do not express estrogen receptor endogenously). Although FGF is a potent mitogen for ®broblasts, FGF treatment caused a similar (®vefold) reduction of ERE-CAT activity in cells treated with estrogen ( Figure 4b ). The Bek 2.0 kb construct was unable to block the inhibitory eect of FGF in the NIH3T3 cells. This is most likely due to the high level of endogenous FGF receptors expressed on NIH3T3 cells that cannot be suciently blocked by the transfected truncated receptor. On the other hand, expression of the activated FGFR-2 had an eect very similar to that observed in MCF-7 cells. This repressive eect of FGF on estrogen-stimulated ERE-CAT activity is not seen In vitro kinase assay. Cells were treated with 100 nM estradiol, 100 ng/ml FGF-2, 100 ng/ml FGF-4, or 100 ng/ml EGF for 30 min and lysed. Active MAP kinase was immunoprecipitated, and elk-1 was added as a substrate. Phosphorylated elk-1 was detected using an anti-phospho-elk-1 antibody. (b) Time course of MAP kinase activation by Western analysis of whole cell lysates. MCF-7 cells were treated as indicated, lysed, and subjected to SDS ± PAGE. Active MAP kinase and MAP kinase (erk2) were detected by immunoblotting. FGF-2 was at 10 ng/ml and estrogen at 10 nM. (c) Time course of MAP kinase activation in T47D cells. Cells were treated with 10 ng/ml FGF-2 (F) for the indicated times or IFN-g (I) as a control. Whole cell lysates were subjected to Western analysis with anti active MAP-kinase antibodies in T47D cells (data not shown). In fact, in these cells FGF was able to induce ER-mediated transcription in an estrogen-independent manner (data not shown). This eect is similar to that previously reported for EGF and IGF in other cell types (Kato et al., 1995) .
FGF can modulate the level of progesterone receptor mRNA
Estrogen regulates the mRNA level of several genes that have an ERE in the promoter region. We looked at the expression of progesterone receptor (PR) which is upregulated by estrogen (Katzenellenbogen and Norman, 1990 ). Figure 5 shows that estrogen can induce the expression of PR by 6 h in MCF-7 cells. FGF treatment clearly inhibits the estrogen eect and results in a lower steady-state level of PR mRNA after 24 h.
The inhibitory eect of FGF is independent of MAP kinase phosphorylation of ER Ser 118
The serine 118 residue in the N-terminal activation domain of ER is a substrate for MAP kinase and is essential for the growth factor-induced ligand-independent activity of ER (Kato et al., 1995; Bunone et al., 1996) . We tested whether the inhibitory eect of FGF on ER activity was mediated by phosphorylation at this site. A mutant S118A ER was transfected into NIH3T3 cells along with the ERE-CAT reporter construct, and estrogen and FGF were applied as before. Figure 6 shows that CAT activity induced by the S118A mutant ER is still inhibited by FGF although the estrogen-inducibility is slightly reduced compared to wild type ER. The level of ER transiently expressed in these cells was determined by Western blot to be approximately equal within each transfection group (data not shown).
p21/WAF-1 is induced by FGF in MCF-7 cells
We looked for changes in the levels of known G1 cell cycle inhibitory proteins that may provide clues about the nature of the FGF inhibitory eect. We found that the level of cyclin D1 in FGF-treated cells was unchanged at 22 h but upregulated at about 5 h both in the presence and absence of estrogen (Figure 7b ), while the level of the cdk inhibitor p27/kip-1 was unchanged over 22 h. However, the cdk inhibitor p21/ waf-1 was induced by the FGFs, particularly by FGF-2 (Figure 7a) . Interestingly, the level of induction produced by dierent FGFs correlated with the extent of the inhibitory eect, with FGF-2 being the strongest and FGF-7 being the weakest. p21 levels in clone 1021 #18, which expresses the activated FGF receptor, are much higher than in MCF-7 cells and are unchanged by FGF treatment (Figure 7a , right panel). T47D cells under the same conditions showed no detectable induction of p21 by FGF (data not shown). Figure  7b shows that the level of p21 induced by FGF remains elevated for at least 22 h.
The induction of p21 by FGF is also seen at the level of mRNA. In MCF-7 cells treated with FGF4 for 48 h, p21 mRNA is induced (Figure 8) . The induction by FGF is seen at 1 h and is unaected by the presence of estrogen (data not shown). There is no further induction of p21 by FGF treatment in 1021 #18 cells where the basal p21 level is much higher than in MCF-7 parental cells. Figure 5 Northern blot analysis. MCF-7 cells were treated as indicated, and mRNA was prepared. Blotting was performed with 3.1 kb BamHI fragment from the human progesterone receptor (PR) and 0.6 kb PstI fragment from the rat glyceraldehyde phosphate dehydrogenase messages Figure 6 CAT assay with wild type and S118A mutant ER. NIH3T3 cells were transfected with the ERE-CAT construct and either wild type estrogen receptor or the phosphorylation site (S118A) mutant receptor, and treated as indicated
STAT1 is phosphorylated upon FGF treatment of MCF-7 cells
The inhibitory eect of FGF on MCF-7 cells and the sustained induction of p21 that it causes, is uncharacteristic in light of the mitogenic properties of FGF on many cell types. We reasoned that this eect might be via a signaling mechanism that is independent of the ras-MAP kinase pathway. A signaling pathway originally associated with growth arrest was the JAK-STAT pathway in which the JAK family of tyrosine kinases phosphorylate and activate STAT proteins (Darnell et al., 1994; Ihle and Kerr, 1995) . STAT activation in response to EGF and interferon (IFN)-g has been associated with growth inhibition and induction of p21 (Chin et al., 1996) . We determined whether FGF treatment activated the STAT pathway in MCF-7 cells. Figure 9 shows a Western blot performed with antibodies directed speci®cally against phosphorylated STAT1. FGF treatment induces a very signi®cant level of phosphorylation of STAT1 within 5 min, which decreases progressively with time but is still detectable at 18 h after FGF addition. As expected STAT1 phosphorylation is strongly induced by IFN-g treatment. On the other hand, induction of STAT1 phosphorylation by FGF in T47D cells is barely detectable, while IFN-g can still strongly induce its phosphorylation. The lower panel is a Western blot using antibodies directed against STAT1. This result was con®rmed by immunoprecipitation with anti-STAT1 antibodies and immunoblotting with antiphosphotyrosine antibodies (data not shown). We did not detect phosphorylation of other STAT molecules. Immunoprecipitation with anti-STAT2, STAT3, or STAT5 antibodies and anti-phosphotyrosine immunoblotting revealed no activation of these STATs by FGF in MCF-7 cells (data not shown).
Discussion
Breast tumors are a mix of epithelial, stromal and vascular components, but the interactions between these cell types are not well de®ned. Although the malignant cells are epithelial in origin, growth factors provided by the stromal cells probably play an important role in regulating epithelial cell growth. Expression of FGF-2 in human breast tissue was consistent with this assumption since FGF-2 was found localized to the basement membrane and in the myoepithelial cells, but not in the luminal epithelial cells (Gomm et al., 1991) . MMTV-induced mouse mammary tumors are thought to arise by autocrine stimulation of mammary epithelial cells due to activation of growth factor gene expression by viral integration (Peters, 1991) . In transgenic animals expressing int-1, infection with MMTV leads to a high incidence of mammary carcinomas. These tumors often express int-1 together with FGF-3 or FGF4, suggesting that these factors act in cooperative ways to promote mammary carcinogenesis in mice (Shackleford et al., 1993; MacArthur et al., 1995) . In humans, the response to these growth factors may normally be directly or indirectly under hormonal control. As tumors progress, they often become hormone-independent and therefore resistant to anti-estrogenic therapies. Genetic or epigenetic events leading to unregulated activation of growth factor signaling pathways probably enables the tumor cells to bypass or be less responsive to hormonal control and thus become more malignant. This appears to be the case in the Dunning rat prostate tumor model where FGFs --FGF4  FGF4  E2  E2  E2+FGF4  E2+FGF4 p21 GAPDH
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Time Treatment Figure 9 MCF-7 and T47D cells were treated with 100 ng/ml FGF2 (F) or 150 ng/ml IFN-g (I) as a positive control and harvested at the indicated timepoints. Lysates were subjected to Western blotting using antibodies directed against Stat1 and phosphorylated Stat1
and FGFR-2 genes are activated in malignant epithelial cells, an event which presumably frees them from dependence on stromally-derived FGF-7 (Yan et al., 1993) . We were originally interested in determining what factors were involved in converting cells from an estrogen-dependent state to an estrogen-independent one. Based on the prostate model, we originally set out to test the hypothesis that autocrine FGF production by mammary epithelial cells enabled them to bypass the requirement for estrogen. However, inhibition of FGF signaling in the estrogen-unresponsive HBL100 breast epithelial cell line, which produces FGF-2, did not restore estrogen responsiveness (our unpublished results). Furthermore, when we expressed constitutively activated FGF receptors in the hormone dependent MCF-7 cells, expecting that we could bypass the hormone requirement by activating a constitutive growth factor signaling pathway, we found that the clones expressing the activated FGF receptors grew poorly and still required estrogen for growth. We therefore set out to investigate this ®nding by comparing the eects of FGF signaling in the ERpositive breast cell line MCF-7, and in the T47D cell line, which is estrogen-responsive but expresses ER at a much lower level.
As described in this report, we were able to show that FGF signaling has an inhibitory eect on the growth of MCF-7 cells with an increased frequency of cells in G1 phase of the cell cycle. FGF also has a repressive eect on estrogen-induced transcription as seen by the inhibition of ERE-CAT activity and by Northern analysis of PR, an estrogen-regulated gene.
The inhibitory eect appears to be mediated by the cdk inhibitor p21 which is strongly induced by FGF. T47D cells are not growth inhibited by FGF, show no inhibition of an estrogen-inducible CAT reporter, and no induction of p21. Increasing the level of FGF signaling by overexpression of an activated FGFR-2 (1021) strongly inhibited cell growth and the expression of the ERE-CAT plasmid. Cells expressing FGFR-2/ 1021 also had elevated levels of p21 and activated MAP kinase in the absence of exogenous FGF treatment, indicating that the activated receptor was functional in these cells. Thus FGF and estrogen have opposing functions in MCF-7 cells and FGFs may have a role in modulating the estrogen response and epithelial cell growth and in breast tissues.
These results were somewhat surprising in view of the hypothesis that autocrine growth factor loops can relieve the need for estrogen stimulation in breast cancer cells. The data in the literature about the eects of FGFs on breast epithelial cells is, however, con¯icting. As in the prostate model, it was assumed that stromally derived FGFs stimulate the growth of epithelial cells. Acquisition of an autocrine FGF growth loop would then free the cells from stromal control during tumor progression. Supporting this hypothesis is the ®nding that certain ER-negative breast tumor-derived cell lines express some of the FGFs (Dickson et al., 1986; Ethier, 1995) ; and MCF-7 cells transfected with a cDNA encoding FGF-4 formed tumors in ovariectomized mice (McLesky et al., 1993) . These latter data contrast with our ®ndings, but it should be noted that the major dierence found by these authors between FGF-4-expressing MCF-7 and parental MCF-7 cells is the ability of the FGFexpressing cells to form tumors in vivo, where the angiogenic ability of FGFs could play a role. It is also interesting to note that MDA-MB-134 cells which overexpress FGFR-1 and maintain an estrogen response, are growth inhibited by FGF (McLeskey et al., 1994) .
It is now also becoming increasing clear that the FGF eect on breast epithelial cells is not like that of EGF i.e., FGF does not activate ER in a ligandindependent manner. Studies of FGF-1 and FGF-2 expression in breast tumor biopsies showed that they are expressed at lower levels in tumors (Bansal et al., 1995; Yiangou et al., 1997) . The loss of FGF-2 expression correlated with poor prognosis as well, pointing to a negative regulatory role for FGF in breast tumor development. Also, expression of FGFs has not been found to be elevated in mammary tumors that are not MMTV-induced (Coleman-Krnacik and Rosen, 1994) . have recently reported a ®nding similar to ours; that FGF-2 has a growth inhibitory eect on MCF-7 cells in spite of activating MAP kinase but the eect on the estrogen response has not previously been described.
It is unlikely that MAP kinase is mediating the inhibitory eect of FGF since all the FGFs tested are able to strongly activate MAP kinase while having dierent inhibitory eects, and T47D cells respond to FGF treatment with MAP kinase activation, but are not growth inhibited and do not upregulate p21 expression. Also, the major MAP kinase target, serine 118 of ER, does not appear to be involved in the inhibitory eect on the estrogen-inducible CAT activity in NIH3T3 cells. In PC12 cells, the decision to proliferate or dierentiate is thought to be made based on the amplitude and duration of the MAP kinase signal (Marshall, 1995) , and in NIH3T3 cells expressing trkA, NGF inhibits growth via activation of the MAP kinase pathway (Pumiglia and Decker, 1997). Use of the mek-1 inhibitor PD98059 did not abolish the growth-inhibitory eect of FGF, but it is possible that the residual active MAP kinase is sucient for inhibition (data not shown). Thus the possibility that the duration of the MAP kinase signal is regulating the inhibitory eect cannot be entirely ruled out.
While our results clearly show a dual eect of FGF signaling in MCF-7 cells, inhibition of growth and down-regulation of estrogen receptor-mediated gene expression, the question of whether these eects are independent of each other or mediated by the same primary eector remains to be answered.
We found that FGF induces phosphorylation of STAT1 and elevates levels of p21, and it is likely that the negative eect on the growth rate is mediated by p21 activity. p21 can negatively regulate the activity of several cyclin-cdk complexes (Sherr and Roberts, 1995) . One such G1 cyclin, cyclin D1, has been shown to be essential for proliferation of breast epithelium; mice lacking cyclin D1 show a defect in proliferation of the estrogen-responsive breast epithelium during pregnancy (Sicinski et al., 1995) . Wang et al. (1997) have recently also reported an FGF-induced elevation of p21 in MCF-7 cells which correlated with a disappearance of active cdk2, (a cyclin D1 partner) and dephosphorylation of Rb. These authors also found an increase in p21-associated PCNA, cyclin D1, and cyclin E, strongly indicating that the p21 increase is at least partly responsible for the growth inhibition. p21 expression is transiently induced by growth factors in cycling cells but does not lead to cell cycle arrest (Michieli et al., 1994) . On the other hand, sustained expression of p21 (as is seen in MCF-7 cells with FGF treatment) is associated with growth inhibition (Halevy et al., 1995) . A recent report by Su et al. (1997) shows that a constitutively activated FGFR-3 can activate STAT1, leading to an upregulation of p21 and cell cycle arrest. EGF induces STAT1 only in A431 cells where it is growth inhibitory, and a link between STAT activation and p21 induction has been established (Chin et al., 1996) . Thus the inhibitory eect of FGF on growth in MCF-7 cells is likely to be via a similar mechanism.
A possible mechanism by which elevated p21 might also lead to the down-regulation of the estrogen response is suggested by some recent ®ndings. Zwijsen et al. (1997) showed that cyclin D1 was able to bind ER in the absence of a cdk partner to activate ERmediated transcription and that the binding of cyclin D1 to ER is via the hormone binding domain of ER. Furthermore, Trowbridge et al. (1997) have recently shown that the cycA/cdk2 complex can phosphorylate ER and enhance its transcriptional activity. Therefore, it may be possible that p21 inhibits ER-mediated transcription either by blocking cyclin/cdk phosphorylation of ER, or by sequestering cyclin D1 in a complex that prevents it from binding ER. We have looked at the eect of increasing p21 levels on the estrogen-induced CAT activity in MCF-7 and NIH3T3 cells by cotransfecting varying amounts of a p21-encoding expression plasmid. Preliminary results indicate that higher p21 levels cause a modest inhibition of the estrogen response (data not shown). Although it may be possible that the mechanisms for growth inhibition and down-regulation of the estrogen response are dierent, they may both be mediated through dierent activities of p21. The activation of the STAT-1 pathway and sustained p21 induction has not been generally observed following stimulation of FGF receptor signaling (Silvennoinen et al., 1993) . This is perhaps not surprising, as FGF signaling has been studied mainly in the context of mitogenic induction, but it does raise the question of why FGF would activate a signal transduction pathway in MCF-7 cells that is not seen in other cells. While super®cially our data could be consistent with the hypothesis that the presence of ER in¯uences the mode of FGF signaling, this hypothesis is at present totally speculative. Another possibility is suggested from the recent ®ndings that signaling by a mutant FGFR-3 can induce STAT-1 activation leading to p21 induction (Su et al., 1997) . While our data suggest that this may not be exclusively related to FGFR-3 (our 1021 construct is a mutant of FGFR-2) it could be thought that this pathway is activated by speci®c FGF receptor heterodimers, perhaps including FGFR-3. It is interesting to note that MCF-7 cells express ®ve types of FGF receptor isoforms, thus permitting a variety of combinations of receptor heterodimers, while fibroblasts generally express only FGFR-1 and FGFR-2 (Li et al., 1994) . We are currently investigating this hypothesis.
Materials and methods
Cell lines
MCF7 and T47D are estrogen-responsive breast cancer cell lines. BT549, MDA-MB-231 and H578T are estrogen receptor-negative tumor lines. HBL100 and H578Bst are derived from normal mammary epithelial cells. These lines were obtained from ATCC and were maintained in Dulbecco's Modi®ed Eagle's Medium (DMEM) supplemented with 10% fetal calf serum (FCS), and 100 units/ml penicillin and 100 mg/ml streptomycin (P/S). NIH3T3 cells are a mouse ®broblast cell line grown in DMEM supplemented with 10% calf serum. 1021 #18 cells were obtained by calcium phosphate transfection of MCF7 cells with a plasmid containing the activated murine FGFR-2 mutant C382R in the pRK5 vector (Li et al., 1997) , and selection by neomycin resistance. 1021 #18 cells were maintained in DMEM+10% FCS+400 mg/ml Geneticin (Life Technologies, Grand Island, NY).
Reverse-transcriptase PCR cDNA was synthesized from 2 mg heat-denatured total RNA in 20 ml total volume. PCR was performed using 1 ml of the reverse-transcription reaction product in a 40 ml reaction containing 1 U TAQ polymerase (Perkin Elmer, Foster City, CA) in reaction buer plus 200 mM dNTPs, 200 ng of each primer, and 1.5 mM MgCl 2 . Thirty-®ve cycles of 45 s at 948C, 1 min at 558C, and 2 min at 728C were followed by a ®nal extension of 9 min at 728C. Products were electrophoresed on 1% agarose gels, transferred to nylon ®lters and subjected to Southern blot analysis using the appropriate 32 P-labeled random-primed probes as described previously (Ittman and Mansukhani, 1997) , and exposed for autoradiography.
Flow cytometry
Cells in 6 cm dishes were kept in phenol red-free DMEM (Mediatech) supplemented with 5% charcoal-stripped fetal calf serum. Treatments were applied for 24 h after which the cells were trypsinized and spun in a microfuge. The cell pellets were washed with phosphate-buered saline (PBS), resuspended in 1 ml and transferred to 15 ml Falcon tubes. Fixing was done with the addition of 4 ml of ice-cold 80% ethanol with simultaneous vortexing and overnight incubation at 48C. Cells were recovered by centrifugation, pellets were air-dried and resuspended in 800 ml PBS containing 200 mg/ml RNase A for 2 h at 378C. Cells were stained with 0.2 ml 56propidium iodide (200 mg/ml propidium iodide, 40 mM sodium citrate, pH 7) for 1 h and DNA content was analysed on a FACScan¯ow cytometer. The percentage of cells in G0/G1, S and G2/M was determined by ModFit software.
CAT assays
MCF-7 and NIH3T3 cells were plated at 1.5610 6 cells/ plate on 10 cm plates and allowed to attach overnight. The following day, plates received fresh DMEM+10% FCS, and were transfected several hours later by calcium phosphate. All transfections were performed with 10 mg DETCO (a plasmid containing the chloramphenicol acetyltransferase gene under the control of an ERE inserted upstream of a minimal thymidine kinase promoter (7109) and 3 mg CMV-b gal (a plasmid constitutively expressing the b-galactosidase gene under the control of the CMV promoter) as an internal control. Where indicated, the plates also received either 8 mg of plasmid encoding murine wild type FGFR-2, or equimolar amounts of plasmid 1021 encoding activated murine FGFR-2, or dominant negative FGFR-2, or pRK5 vector. NIH3T3 cells were also cotransfected with 10 mg of plasmid encoding either the wild type human estrogen receptor or the S118A mutant under the control of the CMV promoter. Sixteen hours after application of calcium phosphate precipitate, plates were washed with PBS and fed fresh phenol red-free DMEM+5% charcoal-stripped fetal calf serum (CS-FCS). Cells were washed and refed three times over the next 8 h, and treated overnight with 10 nM 17-b-estradiol, 10 ng/ml FGF4, or both. Cells were harvested, resuspended in 250 mM Tris, pH 7.4, and lysed by ®ve cycles of freezing and thawing. Clari®ed lysates were used in CAT assays using 14 C-chloramphenicol and analysed by thin layer chromatography. Fractional conversion was calculated by phosphorimager analysis, adjusted by b-galactosidase assay readings, and normalized to the fractional conversion of untreated cells to yield relative CAT activity.
Tritiated thymidine incorporation
Cells that had been growing for 1 week in phenol red-free DMEM supplemented with 5% CS-FCS were plated at 3610 4 cells per well in 24-well plates. The following day, cells were starved in phenol red-free DMEM+0.5% CS-FCS. Two days later the cells were supplemented with 0, 1, or 10 nM estradiol, and 0, 1, or 10 ng/ml FGF4 and incubated overnight. Cells were labeled for 6 h with 1 mCi/ ml 3 H-labeled thymidine, and treated with 10% trichloroacetic acid at 48C overnight, washed, and lysed in 0.5 M NaOH. Samples were neutralized with 0.5 M HCl, added to scintillation cocktail, and counted.
In vitro kinase assays
In vitro MAP kinase assays were performed using the MAP Kinase Assay Kit according to the manufacturer's instructions (New England Biolabs, Beverly, MA). Brie¯y, 2610 6 MCF7 cells were plated on 10 cm plates, serum-starved and estrogen-deprived overnight, treated for 30 min with 100 ng/ml FGF2, FGF4, or EGF, or 100 nM estradiol, harvested and lysed. Clari®ed lysates were immunoprecipitated using phospho-speci®c MAP kinase antibodies. Kinase reactions included the immunoprecipitates and elk-1 as a substrate for MAP kinase. The reactions were subjected to SDS ± PAGE, and immunoblotted using phospho-speci®c Elk-1 antibodies.
Western blots and antibodies
Protein samples were subjected to SDS ± PAGE and transferred to nitrocellulose ®lters. Western blot analysis was performed according to standard protocols and developed by enhanced chemiluminescence (Amersham). Anti-p21, anti-p27, and anti-cycD1 (mouse monoclonal antibodies) were from Transduction Laboratories (Lexington, KY). Anti-ER (HC-20, rabbit polyclonal) and anti-ERK2 (C-14, rabbit polyclonal) were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-active MAP kinase polyclonal antibody was from Promega (Madison, WI). Anti phospho-Stat-1 was from New England Biolabs (Beverley, MA). Anti-Stat-1 rabbit polyclonal antibodies were obtained from David Levy, NYU Medical Center. Sheep anti-mouse and donkey anti-rabbit secondary antibodies, and enhanced chemiluminescence reagent were from Amersham (Arlington Heights, Illinois).
Northern blots
Estrogen-deprived MCF-7 or 1021 #18 cells were treated as indicated mRNA was puri®ed from 250 mg of total RNA using the Oligotex mRNA kit (Qiagen, Chatsworth, CA). Samples were run out on formaldehyde-containing 1% agarose gels and transferred to Genescreen ®lters, which were hybridized using the appropriate probes and imaged by autoradiography and/or phosphorimager (Molecular Dynamics).
